Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Lundbeck to present eight new analyses on bexicaserin at AES 2025, reinforcing sustained seizure-reduction potential across DEEs

Written by | 6 Dec 2025

Lundbeck A/S (Lundbeck) announced that new pipeline data regarding bexicaserin (LP352), a novel investigational drug for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs), will… read more.

UCB announces 21 data presentations spanning clinical research and real-world insights at AES 2025

Written by | 5 Dec 2025

UCB, a global biopharmaceutical company, today announced it will present 21 abstracts at the American Epilepsy Society (AES) Annual Meeting (December 5-9, 2025). Data include primary efficacy and… read more.

AstraZeneca unveils 65 haematology abstracts at ASH 2025, including first cell therapy data

Written by | 5 Dec 2025

AstraZeneca advances its ambition to redefine haematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and… read more.

Xenon to present long-term Azetukalner results and lead patient-provider symposium at AES 2025

Written by | 5 Dec 2025

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, announced multiple presentations at the upcoming American… read more.

Jaypirca to feature in multiple late-breaking and pivotal presentations as Lilly showcases broad BTK inhibitor progress at ASH 2025

Written by | 4 Dec 2025

Eli Lilly and Company announced that data from studies of Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, will be presented at the… read more.

Eli Lilly to share late-breaking and new Phase III results highlighting continued momentum in breast oncology at SABCS 2025

Written by | 3 Dec 2025

Eli Lilly and Company announced that new data from across its breast oncology portfolio and pipeline will be featured at the San Antonio Breast Cancer Symposium (SABCS), taking… read more.

Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS

Written by | 2 Dec 2025

Summary Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker Scemblix data across clinical and real-world settings… read more.

Community pharmacy prescribers improve patient access and release GP time

Written by | 29 Nov 2025

Clinical Pharmacy Congress North – Congress highlights Early results from the community pharmacy independent prescribing (IP) pathfinder programme show that the community pharmacy is increasing patient access to… read more.

HRT prescribing and the Davina effect

Written by | 28 Nov 2025

Clinical Pharmacy Congress North – Congress highlights National prescribing of transdermal and vaginal HRT and micronised progesterone increased while prescribing of oral HRT decreased after the documentary Sex,… read more.

Iluvien (fluocinolone acetonide) implants provide prolonged benefits for uveitis patients

Written by | 27 Nov 2025

Clinical Pharmacy Congress North – Congress highlights A drug-eluting implant has been shown to reverse cystoid macular oedema and reduce the need for systemic treatment in 80% of… read more.

Roche to showcase new data across its haematology portfolio highlighting progress in haemophilia, lymphoma and myeloma at ASH 2025

Written by | 15 Nov 2025

Roche announced that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading haematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition,… read more.

Agios to share new insights reinforcing mitapivat’s potential across multiple rare hematologic diseases at ASH 2025

Written by | 14 Nov 2025

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on mitapivat, an oral pyruvate… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.